利福喷汀联合异烟肼预防糖尿病患者结核病(PROTID):随机对照试验方案
PROTID试验将纳入3000例HIV阴性、糖尿病合并潜伏性结核感染的成人,随机分配至12周利福喷汀联合异烟肼(3HP)方案组或安慰剂组,主要结局为确诊或疑似结核病。另设约1000例LTBI阴性平行队列比较结核发病率,并开展LTBI患病率、成本效果等子研究。
要点
- 3000例糖尿病合并LTBI的HIV阴性成人随机接受12周3HP方案或安慰剂。
- 主要结局为确诊或疑似结核病,采用意向性分析,Poisson回归校正研究现场。
- 另连续纳入约1000例LTBI阴性者入平行队列,比较LTBI阴性与阳性者的结核发病率。
核心结论
- PROTID试验旨在为糖尿病患者这一结核病预防重点人群使用结核预防性治疗提供关键证据,以助力全球结核病控制。
研究设计与样本
- PROTID联盟将在坦桑尼亚和乌干达转诊医院的糖尿病门诊筛查成人患者,随机分配3000例HIV阴性、糖尿病合并LTBI(结核菌素皮肤试验或干扰素γ释放试验阳性)的合格成人至12周3HP方案组或安慰剂组。
- 排除既往结核病或过去2年内使用过利福霉素类药物或异烟肼的患者。
- 另连续纳入约1000例LTBI阴性、HIV阴性参与者进入平行队列研究,比较糖尿病合并LTBI阴性与阳性者的结核发病率。
- 开展多项子研究,包括LTBI和活动性结核患病率、LTBI治疗的人群影响与成本效果、以及结核病-糖尿病共病的预防和治疗管理缺口。
关键数值与推荐
- 主要结局为确诊或疑似结核病的发生;次要结局包括不良事件、全因死亡和治疗完成。
- 主要疗效分析采用意向性分析,同时进行符合方案分析;采用Poisson回归校正研究现场,估计干预组与对照组结核发病率的比值,疗效估计值以1-率比报告。
- 还将报告以死亡为竞争风险的累积发病率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Diabetes mellitus (DM) increases the risk of tuberculosis (TB) and will hamper global TB control due to the dramatic rise in type 2 DM in TB-endemic settings. In this trial, we will examine the efficacy and safety of TB preventive therapy against the development of TB disease in people with DM who have latent TB infection (LTBI), with a 12-week course of rifapentine and isoniazid (3HP). METHODS: The 'Prevention of tuberculosis in diabetes mellitus' (PROTID) consortium will randomise 3000 HIV-negative eligible adults with DM and LTBI, as evidenced by a positive tuberculin skin test or interferon gamma release assay, to 12 weeks of 3HP or placebo. Participants will be recruited through screening adult patients attending DM clinics at referral hospitals in Tanzania and Uganda. Patients with previous TB disease or treatment with a rifamycin medication or isoniazid (INH) in the previous 2 years will be excluded. The primary outcome is the occurrence of definite or probable TB disease; secondary outcome measures include adverse events, all-cause mortality and treatment completion. The primary efficacy analysis will be intention-to-treat; per-protocol analyses will also be carried out. We will estimate the ratio of TB incidence rates in intervention and control groups, adjusting for the study site using Poisson regression. Results will be reported as efficacy estimates (1-rate ratio). Cumulative incidence rates allowing for death as a competing risk will also be reported. Approximately 1000 LTBI-negative, HIV-negative participants will be enrolled consecutively into a parallel cohort study to compare the incidence of TB in people with DM who are LTBI negative vs positive. A number of sub-studies will be conducted among others to examine the prevalence of LTBI and active TB, estimate the population impact and cost-effectiveness of LTBI treatment in people living with DM in these African countries and address gaps in the prevention and therapeutic management of combined TB-DM. DISCUSSION: PROTID is anticipated to generate key evidence to guide decisions over the use of TB preventive treatment among people with DM as an important target group for better global TB control. TRIAL REGISTRATION: ClinicalTrials.gov NCT04600167 . Registered on 23 October 2020.
引用
- Ntinginya NE, Te Brake L, Sabi I, et al. Rifapentine and isoniazid for prevention of tuberculosis in people with diabetes (PROTID): protocol for a randomised controlled trial. Trials. 2022. PMID: 35689272. doi:10.1186/s13063-022-06296-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。